{"filings":[{"id":49924,"accession_number":"0001104659-26-059751","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2026-05-13T11:00:54+00:00","items":["5.02"],"status":"ready","headline":"AptarGroup names Aditya Gandhi CAO; effective June 8, replaces Ackerman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aditya Gandhi appointed Vice President, CAO; effective June 8, 2026.","Daniel Ackerman steps down as CAO but remains in another leadership role.","Gandhi previously CAO at Sonoco Products (Aug 2022-May 2026).","Offer letter: $105,000 sign-on bonus (pro-rata repayment if leave <2 yrs).","One-time equity award of $715,000 ($305K RSUs + $410K performance RSUs)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99573,"accession_number":"0001104659-26-057084","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AptarGroup shareholders reelect four directors, approve say-on-pay and auditor ratification at May 6 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Fotiades, Matthews, Owens, and Xing reelected; support ranged from 49.6M to 54.1M votes.","Advisory vote on executive compensation passed with 53.4M for vs 1.1M against.","Ratification of PricewaterhouseCoopers as auditor for FY 2026 approved with 56.1M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99572,"accession_number":"0000896622-26-000090","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptar Q1 adjusted EPS $1.19 (-8% YoY); names Gael Touya CEO effective Sept 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales up 11% to $982.9M; core sales flat; net income down 8% to $73M.","Adjusted EPS $1.19 vs. $1.30; adjusted EBITDA margin 19.2% vs. 20.7%.","Pharma core sales -1% (prescription -10% on emergency medicine destocking; injectables +20%).","Beauty core sales +3%; Closures core flat; both segments saw margin compression.","Q2 2026 adjusted EPS guidance $1.32-$1.40; declared $0.48 dividend payable May 27."],"consensus_eps_estimate":1.1629,"consensus_eps_actual":1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":982868000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115651,"accession_number":"0001104659-26-029612","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AptarGroup CEO Stephan Tanda to retire Sept 1, 2026; Gael Touya appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Tanda to retire effective Sep 1, 2026; will serve as strategic advisor through Dec 31, 2026 and remain on Board until year-end.","Gael Touya, currently president of Aptar Pharma, named President & CEO effective Sep 1, 2026; also to join Board.","Touya employment agreement: base salary $1,060,000, target bonus 120%, LTI target 500% of base salary; €2.5M deferred compensation payout.","Retention equity awards: CFO Vanessa Kanu receives $1.3M in RSUs (3-year cliff); Closures president Hedi Tlili receives $1.3M (2-year cliff)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115650,"accession_number":"0000896622-26-000004","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptar Q4 net income down 26%, adjusted EPS $1.25 vs $1.62; new $600M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales +14% to $963M (core +5%); net income -26% to $74M ($1.13 EPS).","Adjusted EPS $1.25 vs $1.62; adjusted EBITDA margin 19.8% vs 23.0%.","Pharma core sales +4% (injectables +24%), Beauty +10%, Closures +1%.","Board authorized new $600M share repurchase; Q1 2026 adjusted EPS guidance $1.13-$1.21.","Returned $206M to shareholders in Q4 via buybacks and dividends; quarterly dividend $0.48."],"consensus_eps_estimate":1.2409,"consensus_eps_actual":5.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":3777181000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132084,"accession_number":"0001104659-25-114637","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"AptarGroup closes $600M offering of 4.750% Senior Notes due 2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$600M principal; 4.750% coupon, semi-annual; matures March 30, 2031.","Make-whole call before Feb 28, 2031; at par thereafter; change-of-control put at 101%.","Notes are unsecured, rank equally with existing senior unsecured debt; issued under shelf registration.","Net proceeds not specified; underwriting led by J.P. Morgan, PNC, SG Americas, Wells Fargo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132083,"accession_number":"0000896622-25-000031","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q3 2025: adj. EPS $1.62 (+4% YoY); pharma injectables surge 18%; Q4 adj. EPS guidance $1.20-$1.28","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $961M (+6% YoY); core sales +1%. Reported EPS $1.92 (+30%); adjusted EPS $1.62 (+4%).","Pharma injectables sales surged 18% driven by GLP-1 components; Pharma core sales +2%.","Beauty core sales flat; Closures core sales -1% due to lower tooling and resin pass-throughs.","Q4 adjusted EPS guidance $1.20-$1.28; returned $70M to shareholders in Q3 via repurchases and dividends."],"consensus_eps_estimate":1.5828,"consensus_eps_actual":4.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2814445000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148663,"accession_number":"0000896622-25-000026","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q2 2025: adj. EPS $1.66 (+18% YoY), sales $966M (+6%), adj. EBITDA margin 22.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $966M (+6% YoY); core sales +3%; net income $112M (+24%); adj. EPS $1.66 vs $1.41.","Pharma core +3% (Injectables +9%, Active Material Science +11%); adj. EBITDA margin 35.4% (+130 bps).","Closures core +7% (food & bev); Beauty core +1% (personal care up, fragrance subdued).","Q3 adj. EPS guidance $1.53-$1.61; includes ~$0.06-$0.07 legal fees for pharma IP litigation.","Returned $100M to shareholders ($70M buybacks, $30M dividends); quarterly dividend $0.45 payable Aug 14."],"consensus_eps_estimate":1.579,"consensus_eps_actual":2.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":1853314000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167526,"accession_number":"0001104659-25-045928","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AptarGroup shareholders approve 1M share increase for 2018 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2018 Equity Plan adding 1,000,000 shares approved; 55,973,606 for, 1,397,174 against.","Directors Kampouri Monnas, Marey-Semper, Tanda elected with >53M votes each.","Advisory say-on-pay approved: 55,201,530 for, 2,167,122 against.","Ratification of PwC as auditor for FY2025: 58,926,203 for, 859,697 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167525,"accession_number":"0000896622-25-000012","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q1 2025: sales down 3% to $887M, adjusted EPS $1.20, guides Q2 EPS $1.56-$1.64","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales down 3% to $887M; net income down 5% to $79M; adjusted EPS $1.20 vs $1.22 prior year.","Pharma core sales +3% on drug delivery systems; Beauty core -3% on lower fragrance; Closures core -2%.","Adjusted EBITDA $183M (+3%); margin 20.7% (+120 bps) driven by pharma royalties.","Q2 2025 adjusted EPS guidance $1.56-$1.64; effective tax rate 19%-21% vs 24% adjusted prior year.","Repurchased 548k shares for $80M; quarterly dividend $0.45/share payable May 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":887305000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184819,"accession_number":"0000896622-25-000004","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q4 net income +62% to $101M; adj. EPS $1.52; pharma sales +8% FY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported EPS $1.49 (+60% YoY); adjusted EPS $1.52 (+27% YoY).","Full-year net income $375M (+32%); adjusted EPS $5.64 (+18%).","Pharma core sales +4% Q4; Closures core +7% Q4; Beauty core -3% Q4.","Q1 2025 adj. EPS guidance $1.11-$1.19; currency headwind ~$0.07; tax rate 25-27%.","Board authorized $500M share repurchase; quarterly dividend $0.45/share declared."],"consensus_eps_estimate":null,"consensus_eps_actual":5.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":3582890000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201411,"accession_number":"0000896622-24-000038","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptar reports Q3 net income $100M (+19%), adjusted EPS $1.49 (+6%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $909M (+2% core sales); Pharma segment core sales +7%, Beauty -6%, Closures +4%.","Adjusted EBITDA $208M (23% margin); reported EPS $1.48 vs $1.26 prior year.","Q4 2024 adjusted EPS guidance $1.22-$1.30; full year adjusted EPS outlook $5.34-$5.42, double-digit YoY growth.","Quarterly dividend $0.45/share, payable Nov 14 to holders of record Oct 24; Board authorized $500M share repurchase program.","Pharma drug delivery systems grew double digits; Closures margins up ~200 bps YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":4.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2734802000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217419,"accession_number":"0001104659-24-082706","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Aptar CFO Bob Kuhn to retire Dec 31; Vanessa Kanu named successor effective Jan 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kuhn, CFO since 2008 and 37-year Aptar veteran, steps down Dec 31, 2024; also resigns as principal accounting officer July 31.","Vanessa Kanu, former CFO of TELUS International ($2.7B revenue), becomes CFO designate in Q4 2024 and CFO on Jan 1, 2025.","Kanu's Employment Agreement: $720K base salary, 85% target bonus, 310% LTIP; $700K RSU grant plus $300K sign-on bonus.","Daniel Ackerman named Chief Accounting Officer effective Aug 1, 2024; receives $750K RSU award vesting over 3 years.","Kuhn stays as advisor for 12 months post-retirement at $10K/month to transition responsibilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217418,"accession_number":"0000896622-24-000032","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptar reports Q2 EPS $1.34 (+8% YoY); raises dividend 10% to $0.45","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $910M (+2% reported, +3% core); net income $90M (+9%).","Adjusted EPS $1.37 (+12% YoY) vs. $1.22 prior year; Pharma core sales +7%.","Q3 2024 adjusted EPS guidance range $1.38-$1.46 with tax rate 23.5%-25.5%.","Quarterly dividend raised ~10% to $0.45/share; payable Aug 15, record Jul 25.","Cash from operations $236M YTD (up from $182M); free cash flow $92M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":1825511000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217417,"accession_number":"0001104659-24-077768","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"AptarGroup enters new credit agreement with $600M revolver and $330M term loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $330M unsecured term loan facility maturing July 2, 2027; revolving credit facility extended to July 2, 2029.","Prior $600M revolving credit facility terminated without early termination penalty.","Financial covenants: max consolidated leverage ratio 3.50x, min interest coverage 3.00x.","Initial margins: term loan 1.125% over Term SOFR; revolver 1.00% over Term SOFR; pricing grids based on leverage and ratings.","Up to $300M of additional commitments available subject to conditions and lender consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237267,"accession_number":"0001104659-24-056372","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"AptarGroup shareholders elect three directors, approve officer exculpation amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Sarah Glickman (54.6M for), Matt Trerotola (54.3M), Ralf K. Wunderlich (55.1M) to three-year terms.","Advisory vote on executive compensation approved: 54.9M for, 1.5M against, 3.4M broker non-votes.","Amendment to certificate of incorporation for officer exculpation under Delaware law approved: 50.5M for, 5.9M against.","Ratified PricewaterhouseCoopers as independent auditor for fiscal 2024: 58.6M for, 0.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237266,"accession_number":"0000896622-24-000018","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptar Q1 EPS $1.23 ($1.26 adj) up 50% (31% adj); revenue $915M +6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net income $83M (+52%); adjusted EBITDA $179M (+16%).","Pharma core sales +13% driven by proprietary drug delivery systems; Beauty core -1%, Closures core +1%.","Q2 2024 adjusted EPS guidance $1.30-$1.38; tax rate 22-24%.","Quarterly dividend of $0.41/share payable May 16 to holders of record April 25; $12M in share repurchases.","Lower tax rate of 20.6% vs 25.6% prior year contributed $0.07 EPS benefit."],"consensus_eps_estimate":null,"consensus_eps_actual":1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":915448000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254817,"accession_number":"0000896622-24-000006","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptar Q4 adjusted EPS $1.21 (up 27%), FY 2023 revenue $3.49B, guides Q1 2024 EPS $1.10-$1.18","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported sales $838M (+5%), net income $62M (+6%), adjusted EPS $1.21 vs $0.95 (up 27%).","FY 2023 sales $3.49B (+5%), net income $284M (+19%), adjusted EPS $4.78 vs $3.87 (up 24%).","Pharma core sales +11% in Q4 driven by proprietary drug delivery systems; Beauty -6%, Closures -4%.","Q1 2024 adjusted EPS guidance $1.10-$1.18; expects continued Pharma growth and market recovery.","Dividend $0.41 payable Feb 22; repurchased 81k shares for $10.3M in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":4.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":3487450000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272291,"accession_number":"0000896622-23-000038","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptar Q3 adjusted EPS $1.39 (+39%), net income $84M (+55%), sales $893M (+7%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $84M (+55% YoY), reported EPS $1.26, adjusted EPS $1.39 (+39% YoY).","Core sales +2% overall; Pharma +8% core (double-digit proprietary drug delivery), Beauty +2% core (fragrance), Closures -9% core (resin costs).","Adjusted EBITDA $193M (+26% YoY); free cash flow $97M (+76% YoY).","Q4 2023 adjusted EPS guidance $1.06-$1.14; tax rate 24-26%; currency tailwind ~$0.02.","Quarterly dividend $0.41/share payable Nov 16; Q3 repurchased 66k shares for $8.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":2648970000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272290,"accession_number":"0001104659-23-109096","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"AptarGroup amends bylaws, sets 2024 stockholder proposal window Jan 4 – Feb 3","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaws amended to align with Delaware law updates and universal proxy rules.","Director nomination window shifted to 120–90 days before annual meeting anniversary.","Stockholder proposals for 2024 annual meeting must be received between Jan 4 and Feb 3, 2024.","New disclosure requirements for nominees, including interviews within 10 days of request.","Procedural clarifications regarding proxies, inspectors of election, and gender-neutral language."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289133,"accession_number":"0001104659-23-098329","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"AptarGroup appoints Sarah Glickman to board, effective Sept 5, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sarah Glickman, CFO of Criteo S.A., added to Aptar's Board of Directors on September 5, 2023.","She qualifies as independent director and audit committee financial expert; joins the Audit Committee.","Glickman brings 30+ years of global finance/operations experience at Novartis, Honeywell, and Bristol-Myers Squibb.","Appointment increases board diversity to 5 women out of 10 directors.","Her compensation matches other non-employee directors as described in the 2023 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289132,"accession_number":"0000896622-23-000030","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q2 net income +31% to $83M; raises dividend 8% to $0.41/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported EPS $1.24, adjusted EPS $1.23 (+26% YoY); revenue $896M (+6% reported, +4% core).","Pharma core sales +13%; Beauty +3% (fragrance double-digit); Closures -8% due to lower resin prices.","Board approved dividend increase to $0.41/share (almost +8%); payable Aug 17 to holders of record July 27.","Q3 2023 adjusted EPS guidance $1.23-$1.31; effective tax rate 25%-27%.","Repurchased 81k shares for ~$9.3M in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1755973000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289131,"accession_number":"0001104659-23-080389","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2023-07-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Maritza Gomez Montiel resigns from AptarGroup board effective July 9, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maritza Gomez Montiel resigned from the Board of Directors on July 9, 2023, effective immediately.","No reason for the resignation was disclosed in the filing.","Gomez Montiel had served on the board for many years; no successor announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309889,"accession_number":"0001104659-23-059206","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Andreas Kramvis resigns from AptarGroup board effective May 6, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andreas Kramvis resigned from the Board of Directors on May 6, 2023, after many years of service.","Resignation was effective immediately; no reason provided beyond long tenure.","No replacement named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309888,"accession_number":"0001104659-23-056000","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AptarGroup shareholders approve 2018 Equity Incentive Plan amendment, adding 1.2M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2018 Equity Incentive Plan approved, increasing share reserve by 1,200,000 shares.","All four director nominees elected: Fotiades, Matthews, Owens, Xing, each with majority support.","Advisory vote on executive compensation passed with ~94% of votes cast in favor; one-year frequency approved.","Ratification of PwC as independent auditor for FY2023 approved with ~98% of votes cast in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309887,"accession_number":"0000896622-23-000019","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q1 core sales +4% to $860M; adj. EPS $0.95; guides Q2 adj. EPS $1.11-$1.19","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $860M (+2% YoY); core sales +4% driven by Pharma (+7%) and Beauty (+9%); Closures -8%.","Reported EPS $0.82 (-12% YoY) on restructuring charges; adjusted EPS $0.95 (+2% YoY).","Q2 2023 adjusted EPS guidance $1.11-$1.19 at 26%-28% tax rate and EUR/USD 1.08.","Quarterly dividend $0.38/share, payable May 25, 2023 to holders of record May 4.","Repurchased 171k shares for ~$20M during Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":860067000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309886,"accession_number":"0000896622-23-000014","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AptarGroup realigns segments into Pharma, Beauty, Closures; recasts 2022 & 2021 data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Jan 1, 2023: combined all closures into Aptar Closures; renamed Beauty+Home to Aptar Beauty.","FY 2022 net sales $3.32B (up 2.9% YoY); adjusted EBITDA $616.7M vs $607.5M in 2021.","Aptar Closures FY 2022 adjusted EBITDA margin 11.7%, down from 14.3% in 2021.","Aptar Beauty FY 2022 adjusted EBITDA margin 12.4%, up from 10.6% in 2021.","Recast quarterly and annual segment revenue and adjusted EBITDA furnished for 2022 and 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328586,"accession_number":"0001104659-23-027439","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AptarGroup appoints Julie Xing as independent director effective March 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Julie Xing, 54, appointed to AptarGroup board effective March 1, 2023; term expires at 2023 annual meeting.","Xing is independent under NYSE rules; committee assignments not yet determined.","She serves as Executive Chair of Mundipharma (China) and Board Advisor to Mars; over 20 years in pharma/medtech.","Compensation will match other non-employee directors as described in 2022 proxy statement.","No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328585,"accession_number":"0000896622-23-000005","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q4 core sales up 4%, adjusted EPS $0.92; guides Q1 $0.85-$0.93","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $59M (+2%), reported sales $796M (-2%), core sales +4%; adj EPS $0.92 (+5%).","Pharma segment core sales +8% driven by consumer healthcare and prescription; Beauty+Home core +2%.","Annual 2022 sales $3.32B (+3% reported, +9% core); adj EPS $3.79 (+5%).","Q1 2023 adj EPS guidance $0.85-$0.93; expects continued momentum in Pharma and beauty.","Board declared $0.38 quarterly dividend payable Feb 23; 29th consecutive year of increasing dividend."],"consensus_eps_estimate":null,"consensus_eps_actual":3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":3322249000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346262,"accession_number":"0000896622-22-000029","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q3 net income +15% to $54M; core sales +9%; adj EPS $0.95","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net income $54M (+15%), EPS $0.81 (+16%) vs $0.70.","Adjusted EPS $0.95 (+12% vs $0.85), includes $0.05 one-time inflation payment.","Pharma core sales +20% driven by prescription and allergies; Food +Bev flat.","Q4 adjusted EPS guidance $0.73–$0.83, with $0.08 currency headwind.","Dividend $0.38/share payable Nov 16; $128M remaining for buybacks."],"consensus_eps_estimate":null,"consensus_eps_actual":2.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":2526335000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346261,"accession_number":"0001104659-22-109330","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K/A","filed_at":"2022-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AptarGroup appoints new director Trerotola to Corporate Governance Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew L. Trerotola joined AptarGroup Board effective September 11, 2022.","Appointed to Corporate Governance Committee effective October 13, 2022.","Amendment updates prior 8-K filed September 12, 2022 with committee assignment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362652,"accession_number":"0001104659-22-099299","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AptarGroup appoints Matthew L. Trerotola to board effective Sept 11, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trerotola's term expires at the 2024 annual meeting of stockholders.","Board determined Trerotola is an independent director under NYSE rules.","Trerotola has served as President & CEO of Enovis Corporation (ENOV) since 2015.","Compensation will be consistent with other non-employee directors per 2022 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362651,"accession_number":"0000896622-22-000022","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q2 net income up 15% to $64M; core sales +10%; adjusted EPS $0.96","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $845M (+4% YoY); core sales +10%; net income $64M (+15%).","Adjusted EPS $0.96 (+13% on comparable FX); reported EPS $0.95 (+17%).","Pharma segment core sales +12%; Beauty+Home +10%; Food+Beverage +8%.","Q3 2022 adjusted EPS guidance $0.90-$1.00 (midpoint up ~10% YoY on comparable FX).","Quarterly dividend $0.38/share; bought back 348k shares for $37M in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":1689475000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382229,"accession_number":"0001104659-22-056443","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AptarGroup stockholders elect three directors, approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three director nominees elected: Giovanna Kampouri Monnas, Isabel Marey-Semper, Stephan B. Tanda, each with >56M votes for and ~1M or fewer against.","Advisory vote on executive compensation approved: 56.5M for, 0.8M against, 0.1M abstain (excluding 2.55M broker non-votes).","Ratification of PricewaterhouseCoopers as auditor for fiscal 2022 passed: 58.4M for, 1.1M against, 0.4M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382228,"accession_number":"0000896622-22-000011","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q1 revenue up 9% to $845M; adjusted EPS down to $0.96 from $1.05","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $845M (+9% YoY); core sales +13% with double-digit growth in all segments.","Adjusted EPS $0.96 vs $1.05 prior year; reported EPS $0.93 included $0.19 unrealized gain in prior year.","Pharma core sales +13%; demand for allergic rhinitis and asthma devices recovering.","Q2 2022 adjusted EPS guidance $0.92-$1.02; midpoint +14% on constant-currency basis.","Dividend maintained at $0.38/share; $16M share repurchases in Q1, $184M remaining authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":844932000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400164,"accession_number":"0001104659-22-031040","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2022-03-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"AptarGroup issues $400M 3.600% senior notes due 2032, assumes €300M in subsidiary notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $400M aggregate principal of 3.600% Senior Notes due March 15, 2032, with semi-annual interest.","Assumed €100M 0.98% Notes due 2023 and €200M 1.17% Notes due 2024 from subsidiary AGUK, effective March 1, 2022.","Notes are unsecured, rank equally with other senior unsecured debt; callable at make-whole before Dec 15, 2031.","Change-of-control trigger allows holders to require repurchase at 101% of principal plus accrued interest.","Underwriting agreement with BofA, HSBC, JPMorgan, Wells Fargo; offering under Form S-3 shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400163,"accession_number":"0000896622-22-000004","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q4 sales up 9% to $814M; adjusted EPS $0.93 (+3%); guides Q1 adj. EPS $0.92-$1.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported EPS $0.85 (+8% YoY); adjusted EPS $0.93 (+3% YoY). Net income $58M.","Full-year 2021 sales record $3.23B (+10% reported, +7% core); adjusted EPS $3.88 (+4%).","Pharma segment core sales +8%; Beauty+Home +7%; Food+Beverage +28% in Q4.","Q1 2022 adjusted EPS guidance range $0.92-$1.00; based on EUR/USD 1.14 and tax rate 27-29%.","Dividend held at $0.38/share payable Feb 23; $200M remaining share repurchase authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":3.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":3227221000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400162,"accession_number":"0001104659-22-007397","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2022-01-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aptar appoints Gael Touya as President of Pharma Segment; board classes rebalanced","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Jan 1, 2022, Gael Touya appointed President of Pharma Segment, reporting to CEO Stephan Tanda.","Touya will be based in Congers, NY, on a 3-year assignment (max 5 years).","Compensation includes expatriate benefits: housing, car, education, travel, tax equalization.","His French employment contract with Aptar Europe Holding SAS suspended for assignment duration.","Board rebalanced classes after death of director Joanne Smith; Candace Matthews shifted to 2023 term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419135,"accession_number":"0001157523-21-001284","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AptarGroup Q3 revenue $825M (+9% YoY); adjusted EPS $0.94 vs $1.01; guides Q4 $0.88-$0.96","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $825M, +9% YoY; core sales +8%; Pharma core -2%, Beauty+Home +10%, Food+Beverage +28%.","Reported EPS $0.70 (includes $0.12 restructuring, $0.10 unrealized loss on PureCycle investment, $0.02 acquisition costs); adjusted EPS $0.94.","Adjusted EBITDA $154M; net income $47M.","Completed acquisitions: 80% of Weihai Hengyu Medical Products and majority stake in Voluntis.","Q4 2021 adjusted EPS guidance $0.88-$0.96; quarterly dividend $0.38/share payable Nov 17, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":2.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2413228000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436684,"accession_number":"0001157523-21-000953","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2021-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aptar Q2 sales up 16% to $811M, adj EPS $0.91 (+7%), core sales +10%; Q3 guidance $0.90-$0.98","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $811M (+16% YoY); core sales +10% aided by double-digit growth in Beauty+Home and Food+Beverage.","Reported EPS $0.81 (+29%); adj EPS $0.91 (+7% neutralizing currency); net income $55M (+32%).","Pharma core sales +2% as destocking of allergic rhinitis/cough-cold inventory continues; elastomer demand strong.","Free cash flow H1 $39M (down 63%) due to higher capex and working capital; cash from ops $176M (-23%).","Q3 adj EPS guidance $0.90-$0.98; expects gradual improvement through H2 with acceleration toward year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1587786000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436683,"accession_number":"0001104659-21-088834","cik":896622,"company_name":"APTARGROUP, INC.","ticker":"ATR","form_type":"8-K","filed_at":"2021-07-02T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"AptarGroup enters $600M unsecured multicurrency revolver; $112M term loan remains","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New A&R Credit Agreement provides $600M revolving credit facility (incl. $30M swingline); replaces prior $600M facility.","Existing $112M term loan continues under the A&R agreement; matures July 20, 2022.","Revolver matures June 30, 2026, with up to two one-year extension options available.","Financial covenants: max consolidated leverage ratio of 3.50x and min interest coverage ratio of 3.00x.","Applicable margins and facility fees vary with leverage ratio; benchmark rates include LIBOR, EURIBOR, SONIA, SARON."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":7402837787.013617,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}